Role of insulin-like growth factor-1R system in colorectal carcinogenesis

Critical Reviews in Oncology/Hematology

Volumn 66, Issue 2, 2008, Pages 91-98

  Donovan, Erin A ^a   Kummar, Shivaani ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acromegaly; Anti IGF therapy; Epidemiologic studies in cancer; Growth factors

Indexed keywords

4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; AG 538; ANTISENSE OLIGODEOXYNUCLEOTIDE; BMS 536924; BMS 554417; CP 751871; CYCLOLIGNAN PICROPODOPHYLLIN; DI DIABODY; FLUOROURACIL; INSM 18; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 19D12; MONOCLONAL ANTIBODY A12; MONOCLONAL ANTIBODY AMG 479; MONOCLONAL ANTIBODY EM164; MONOCLONAL ANTIBODY HC710; MONOCLONAL ANTIBODY R1507; NVP AEW 541; OSI 906; PROTEIN KINASE INHIBITOR; RECEPTOR ANTIBODY; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACROMEGALY; CANCER RESEARCH; CANCER RISK; COLON CARCINOGENESIS; COLORECTAL CANCER; DRUG RESEARCH; HORMONAL REGULATION; HUMAN; METASTASIS POTENTIAL; NONHUMAN; PROGNOSIS; REVIEW;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 41249093600     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.09.003     Document Type: Review

References (57)

1. Yakar S., Leroith D., and Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16 (2005) 407-420
2. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4 (2004) 505-518
3. Durai R., Yang W., Gupta S., et al. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 20 (2005) 203-220
4. Jehle P.M., Fussgaenger R.D., Blum W.F., et al. Differential autocrine regulation of intestine epithelial cell proliferation and differentiation by insulin-like growth factor (IGF) system components. Horm Metab Res 31 (1999) 97-102
5. Wu Y., Yakar S., Zhao L., et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62 (2002) 1030-1035
6. Akagi Y., Liu W., Zebrowski B., et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58 (1998) 4008-4014
7. Andre F., Rigot V., Thimonier J., et al. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 83 (1999) 497-505
8. Garrouste F., Remacle-Bonnet M., Fauriat C., et al. Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells-evidence for a NF-kappaB-dependent survival mechanism. Cell Death Differ 9 (2002) 768-779
9. Di Popolo A., Memoli A., Apicella A., et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19 (2000) 5517-5524
10. Hakam A., Yeatman T.J., Lu L., et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30 (1999) 1128-1133
11. Weber M.M., Fottner C., Liu S.B., et al. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95 (2002) 2086-2095
12. Nakamura M., Miyamoto S., Maeda H., et al. Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers. Clin Cancer Res 10 (2004) 8434-8441
13. Zhang L., Zhou W., Velculescu V.E., et al. Gene expression profiles in normal and cancer cells. Science 276 (1997) 1268-1272
14. Nosho K., Yamamoto H., Taniguchi H., et al. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clin Cancer Res 10 (2004) 7950-7957
15. Cruz-Correa M., Cui H., Giardiello F.M., et al. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 126 (2004) 964-970
16. Jenkins P.J., Fairclough P.D., Richards T., et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 47 (1997) 17-22
17. Renehan A.G., Bhaskar P., Painter J.E., et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 85 (2000) 3417-3424
18. Baris D., Gridley G., Ron E., et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13 (2002) 395-400
19. Orme S.M., McNally R.J., Cartwright R.A., et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83 (1998) 2730-2734
20. Paterson A.C., Leeding K.S., Bach L.A., et al. More about: prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 92 (2000) 1947-1950
21. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91 (1999) 620-625
22. Kaaks R., Toniolo P., Akhmedkhanov A., et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92 (2000) 1592-1600
23. Hunt K.J., Toniolo P., Akhmedkhanov A., et al. Insulin-like growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 11 (2002) 901-905
24. Giovannucci E., Pollak M.N., Platz E.A., et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9 (2000) 345-349
25. Palmqvist R., Hallmans G., Rinaldi S., et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50 (2002) 642-646
26. Probst-Hensch N.M., Yuan J.M., Stanczyk F.Z., et al. IGF-1. IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 85 (2001) 1695-1699
27. Nomura A.M., Stemmermann G.N., Lee J., et al. Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 158 (2003) 424-431
28. Haydon A.M., Macinnis R.J., English D.R., et al. Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut 55 (2006) 689-694
29. Renehan A.G., Zwahlen M., Minder C., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
30. Hofmann F., and Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10 (2005) 1041-1047
31. Burtrum D., Zhu Z., Lu D., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63 (2003) 8912-8921
32. Haluska P., Shaw H., Batzel G.N., et al. Phase 1 dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. 2007 ASCO annual meeting proceedings, Part I. J Clin Oncol 25 18S (2007) 3586
33. Cohen B.D., Baker D.A., Soderstrom C., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11 (2005) 2063-2073
34. Maloney E.K., McLaughlin J.L., Dagdigian N.E., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63 (2003) 5073-5083
35. Goetsch L., Gonzalez A., Leger O., et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113 (2005) 316-328
36. Wang Y., Hailey J., Williams D., et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4 (2005) 1214-1221
37. Sachdev D., Li S.L., Hartell J.S., et al. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63 (2003) 627-635
38. Lu D., Zhang H., Koo H., et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280 (2005) 19665-19672
39. Perer E.S., Madan A.K., Shurin A., et al. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94 (2000) 1-5
40. Cunningham M.P., Essapen S., Thomas H., et al. Coexpression of the IGF-IR. EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28 (2006) 329-335
41. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004) 221-230
42. Hopfner M., Sutter A.P., Huether A., et al. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 12 (2006) 5635-5643
43. Girnita A., Girnita L., del Prete F., et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64 (2004) 236-242
44. Blum G., Gazit A., and Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278 (2003) 40442-40454
45. Haluska P., Carboni J.M., Loegering D.A., et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66 (2006) 362-371
46. Carboni J.M., Lee A.V., Hadsell D.L., et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65 (2005) 3781-3787
47. Ji Q.-S., Mulvihill M., Franklin M., et al. A novel, potent and selective IGF-1R small molecule inhibitor blocks activation of IGF-1R signaling in vitro and inhibits IGF-1R dependent tumor growth in vivo. Proc Am Assoc Cancer Res 47 (2006) LB-281
48. Resnicoff M., Tjuvajev J., Rotman H.L., et al. Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J Exp Ther Oncol 1 (1996) 385-389
49. Andrews D.W., Resnicoff M., Flanders A.E., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19 (2001) 2189-2200
50. Reiss K., D'Ambrosio C., Tu X., et al. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 4 (1998) 2647-2655
51. Yu Q., Banerjee K., Paterson J., et al. Insulin-like growth factor-binding protein 3: single-agent and synergistic effects with chemotherapeutic drugs on solid tumour models. Proc Am Assoc Cancer Res (2003)
52. Van den Berg C.L., Cox G.N., Stroh C.A., et al. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 33 (1997) 1108-1113
53. Sell C., Rubini M., Rubin R., et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90 (1993) 11217-11221
54. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res 55 (1995) 249-252
55. Karp D.D., Paz-Ares L.G., Blakely L.J., et al. Efficacy of the anti-insulin like growth factor 1 receptor (IGF-1R) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). 2007 ASCO annual meeting proceedings, Part I. J Clin Oncol 25 18S (2007) 7506
56. Tolcher A.W., Rothenberg M.L., Rodon J., et al. A phase 1 pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. 2007 ASCO annual meeting proceedings, Part I. J Clin Oncol 25 18S (2007) 3002
57. Rodon J., Patnaik A., Stein M., et al. A phase 1 study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. 2007 ASCO annual meeting proceedings, Part I. J Clin Oncol 25 18S (2007) 3590